Eugene Braunwald died on April 22 at 96. The American Heart Association announced it the next day; the American College of Cardiology followed; the Medical University of Vienna, where he was born in 1929 before fleeing Nazi persecution as a child, mourned him publicly on April 24. [1] [2] [3] He had a paper in press at the journal Heart Rhythm earlier this same month — 72 years after his first peer-reviewed publication appeared in Circulation Research in 1954, and roughly 1,800 papers later. [4] He died, in other words, with a manuscript waiting for galley proofs. There is no neater obituary frame than the one he wrote himself.

He was, by the count his biographers maintained, the most-cited cardiologist in the history of the field. In a 2013 review of the PubMed corpus, one biographer found that Braunwald "had more publications in the top general medical and cardiology journals than any of the more than 42,000 authors" indexed. [4] He was the founding editor of Braunwald's Heart Disease — the standard cardiology textbook now in its 13th edition — and the long-time editor of Harrison's Principles of Internal Medicine, the textbook every American medical student opens in the first week of clerkships. He served as the founding chair of medicine at UC San Diego in 1968, the chair of medicine at Brigham and Women's Hospital in Boston for 24 years, and the Hersey Distinguished Professor of Theory and Practice of Physic at Harvard Medical School — one of the oldest endowed chairs in American medicine. [5] [3]

His most consequential institutional act was the founding of the Thrombolysis in Myocardial Infarction Study Group at Brigham in 1984. The TIMI Group's clinical trials separated ST-elevation myocardial infarction from non-ST-elevation MI in operational terms — language every emergency department in the United States uses tonight when a patient walks in with chest pain. The TIMI risk score, the bedside calculator the resident uses to decide whether the patient goes to the cath lab, is named for the group. Marc Sabatine, the current chair of the TIMI Study Group, said in a written tribute that the group "will carry forward his legacy and continue his lifelong mission to advance cardiovascular care." [2]

What is harder to convey, in the form of an obituary, is the field-shaping effect. Elliott Antman, Braunwald's protégé at Harvard for forty years, described him to the AHA in 2024 as having "both direct and indirect effects on the improvements in all aspects of cardiovascular care — heart failure, hypertension, coronary artery disease, valvular heart disease and more." [4] Antman's argument, restated this week in tributes from the European Society of Cardiology and the Society for Cardiovascular Angiography and Interventions, is that progress in those subfields accelerated during Braunwald's career and not by coincidence. The field changed at the rate at which his trials reported.

His work began at the dawn of the post-1955 federal research investment. He was hired at the National Heart Institute — now the National Heart, Lung and Blood Institute — in 1955 and became its chief of cardiology and clinical director. He was, by his own telling, lucky to begin his career in the year the federal government discovered that medical research was something a state could fund at scale. [4] He carried that conviction into the rest of his career. The argument that "the physician scientist" is "an endangered species" — the title of his 2014 keynote at the Medical University of Vienna's tenth-anniversary celebration — was both a warning and a job description. [3] He thought the discipline would not survive without the figure he himself had been.

He kept publishing. The Cardiovascular News obituary noted three new publications in October 2025 alone, plus a detailed review of hypertrophic cardiomyopathy that was either in press or recently published in NEJM. [5] [6] The Heart Rhythm paper in press at the time of his death is, on the available reporting, his last manuscript. The form of his career — peer-reviewed papers in continuous sequence, from 1954 to 2026 — is not one many physicians manage even in the most generous interpretation. Braunwald, a 96-year-old emeritus, was still writing at the rate of a junior faculty member.

Tributes published Tuesday and Wednesday from cardiologists with their own institutional standing — Eric Topol, Ashish Jha, Matthew Herper, Jonathan Reiner — used the same phrase in different words. Jha called him "the most important clinician-scholar of the last 50 years." Herper, the Stat News reporter, wrote that "medicine lost a hero this week. It's wrong to say that Eugene Braunwald was A giant of cardiology. Because he was THE giant of cardiology — the biggest force in the field for as long as I've been covering heart disease." [7] These are not eulogies. They are descriptions.

The AHA has established a memorial fund in his name to support cardiovascular research. [8] The Medical University of Vienna will name a lecture theatre at its Center for Translational Medicine the "Eugene Braunwald Auditorium." [3] The 13th edition of Braunwald's Heart Disease will be revised under the editorship he selected; the TIMI Study Group continues at Brigham under Sabatine. [2] The obituary for the field is the field's continuation. The textbook is open on a fellow's desk somewhere in Boston tonight, and the patient with non-ST-elevation MI in an Indianapolis emergency room will be triaged by a TIMI score his clinician learned from a Braunwald paper.

The newspaper sentence that does the work is the simplest one: a working scientist's life ended with a working manuscript. Braunwald died on a Wednesday with a paper in press on a Friday. His textbook will outlive him by editions. The infrastructure of modern cardiology — the trial framework, the risk scores, the diagnostic categories — was built around him over seventy years and will operate around him for the foreseeable future. The man who wrote the book also wrote the field.

-- KENJI NAKAMURA, Tokyo